Kaposi's sarcoma drug shows promise in small trial
NCT ID NCT01412515
First seen Jun 10, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This phase II trial tested the drug everolimus in 11 people with classic or endemic Kaposi's sarcoma, a rare cancer linked to a virus. The goal was to see if the drug could shrink tumors after 6 months. The study was stopped early, but early results suggest some patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Saint Louis
Paris, 75010, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
everolimus
What this could lead to
If successful, this could point toward a new treatment option for Kaposi's sarcoma that does not require lifelong medication.
What could go wrong
This is a very small, early-phase trial that was terminated early, so results are limited. The drug may not work for everyone and can cause side effects like mouth sores or infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.